The presentations underscore Myriad’s commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-driven insights to help guide clinical care and improve outcomes. They follow the recent launch of Precise™ Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profiling, and companion diagnostic options, including evaluation for homologous recombination deficiency (HRD). The suite offers a streamlined testing experience designed to help oncologists recommend personalized treatment plans for their patients.
Precise Oncology Solutions currently includes Myriad’s Precise™ Tumor Test, MyRisk™ Hereditary Cancer Test and its two FDA-approved companion diagnostic tests: MyChoice® CDx and BRACAnalysis CDx®. A new Precise Treatment Registry combines germline, somatic and HRD genetic data to accelerate the pace of precision cancer research and equitable advancements in patient care. Additionally, Myriad recently announced it will expand its strategic partnership with Intermountain Precision Genomics, a service of
Also at ASCO, Myriad will highlight a validation study for its market-leading MyRisk Hereditary Cancer Test with RiskScore®, the first polygenic breast cancer risk assessment clinically and analytically validated for women of all ancestries. Providers can gain critical insights to help identify women with an increased risk of breast cancer who do not have a harmful mutation in well-known breast cancer genes, like BRCA1.
“Cancer prevention and treatment are most effective when informed by genetic insights,” said
Data from Myriad to be presented at the meeting:
A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score for diverse ancestries (Abstract #366104)
Session Type: Poster Session
Date:
Time:
This is the first breast cancer risk model to include breast density, family history and a polygenic risk score (PRS) based on genetically determined ancestry that is validated for diverse populations. The addition of PRS substantially improved risk stratification over TCv8 alone and may allow for a more personalized approach to breast cancer risk reduction.
Ancestry-specific risk of triple-negative breast cancer (TNBC) associated with germline pathogenic variants (PV) in hereditary cancer (CA) predisposition genes (Abstract #377784)
Session Type: Poster Discussion
Date:
Time:
In this population of women who had multigene panel testing, pathogenic variants in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BARD1 were associated with substantial risk of triple-negative breast cancer (TNBC). There were no significant differences in pathogenic variant associated TNBC risks across ancestries. TNBC was reported more frequently in women of African ancestry.
Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer (Abstract #364894)
Session Type: Poster Session
Date:
Time:
This exploratory analysis evaluated the ability of ≥ 33 or ≥ 42 genomic instability score (GIS) thresholds to predict response to platinum-based treatment in patients with triple-negative breast cancer. This study of 204 tumors of mixed BRCA wild-type, BRCA mutations and unknown showed that a GIS of ≥ 33 may be the most appropriate threshold to predict response to platinum-based treatment in patients with TNBC; however, a prospective trial is needed.
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET) (Abstract #371368)
Session Type: Poster Session
Date:
Time:
In this cohort of patients, even when accounting for other clinical factors such as node status, tumor grade, age at diagnosis, and other variables, Myriad’s EndoPredict® Breast Cancer Prognostic Test provided significant information for clinical decisions on extended endocrine therapy.
About
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company presenting multiple studies at the 2022 ASCO Annual Meeting, the company’s expansion of its strategic partnership with Intermountain Precision Genomics to offer a liquid biopsy therapy selection test in 2023, the company’s plan to highlight a validation study for its MyRisk Hereditary Cancer Test with RiskScore at the 2022 ASCO Annual Meeting, and the company’s strategic imperatives under the caption “About Myriad Genetics.” These “forward-looking statements” are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on the company’s operations and the demand for its products and services and the company’s ability to efficiently and flexibly manage its business; the risk that sales and profit margins of the company’s existing molecular diagnostic tests may decline or that the company may not be able to operate its business on a profitable basis; risks related to the company’s ability to generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the company’s tests or the company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the company may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all; the risk that the company may not successfully develop new markets for its molecular diagnostic tests, including the company’s ability to successfully generate revenue outside
Media Contact: | Investor Contact: |
(385) 318-3718 | (801) 505-5067 |
Megan.Manzari@myriad.com | Nathan.Smith@myriad.com |
Source:
2022 GlobeNewswire, Inc., source